Janakiraman Subramanian

机构：Inova Fairfax Hospital, Virginia Cancer Institute · ORCID：0000-0003-0083-9896

发表论文 192 篇 · 总被引 5633 次 · h-index 32

代表论文

• Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer (2024 · Journal of Clinical Oncology · 被引 158)
• Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors (2024 · Cancers · 被引 29)
• Evaluation of a National Quality Improvement Collaborative for Improving Cancer Screening (2022 · JAMA Network Open · 被引 29)
• A review of therapeutic failures in late-stage clinical trials (2022 · Expert Opinion on Pharmacotherapy · 被引 14)
• A Novel EGFR Germline Mutation in Lung Adenocarcinoma: Case Report and Literature Review (2024 · Clinical Lung Cancer · 被引 10)
• Estimated sensitivity profiles of lung cancer specific uncommon BRAF mutants towards experimental and clinically approved kinase inhibitors (2022 · Toxicology and Applied Pharmacology · 被引 8)